Kazia Therapeutics Ltd
Kazia Therapeutics Ltd (ASX:KZA) is listed on the Australian Securities Exchange.
See more information about Kazia Therapeutics Ltd
Kazia Therapeutics will outline anti-cancer drug development strategy at CEO Sessions
Kazia Therapeutics Ltd (ASX:KZA) is developing anti-cancer drugs with its pipeline including two clinical-stage drug development candidates and the company's progress will be outlined at this month's Proactive CEO Sessions.
Chief executive officer James Garner will present to investors at the Sydney CEO Session on Monday, February 18 and at the Melbourne session on Tuesday, February 19.
Its lead candidate is GDC-0084, which entered a phase II clinical trial in March 2018, and Kazia expects initial data early this year followed by other data read-outs.
GDC-0084 is being developed for glioblastoma multiforme, the most common and most aggressive form of primary brain cancer.
Chemotherapy treatment temozolomide is only effective in one-third of patients.
Furthermore, the median survival rate is 12 to 15 months from diagnosis, meaning there is a demand in the market for superior treatments.
Other Kazia Therapeutics Ltd news
- Kazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphoma
2020-09-22 - Kazia Therapeutics bringing a vetted drug class to the brain: Edison
2020-09-09 - Kazia Therapeutics awarded US FDA Orphan Drug Designation to paxalisib treatment for malignant glioma
2020-08-24 - Kazia Therapeutics raises $1.8 million in well supported share placement
2020-05-06 - Kazia Therapeutics extends SPP owing to strong demand
2020-05-04
